CN111671758A - 牛磺罗定在制备抗hiv病毒药物中的应用 - Google Patents
牛磺罗定在制备抗hiv病毒药物中的应用 Download PDFInfo
- Publication number
- CN111671758A CN111671758A CN202010638924.XA CN202010638924A CN111671758A CN 111671758 A CN111671758 A CN 111671758A CN 202010638924 A CN202010638924 A CN 202010638924A CN 111671758 A CN111671758 A CN 111671758A
- Authority
- CN
- China
- Prior art keywords
- taurolidine
- hiv
- virus
- application
- human immunodeficiency
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims abstract description 36
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229960004267 taurolidine Drugs 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 230000036436 anti-hiv Effects 0.000 title claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- 239000003978 infusion fluid Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- -1 infusion Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000002779 inactivation Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 4
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 3
- 208000030507 AIDS Diseases 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 241000700605 Viruses Species 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013068 control sample Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- HMYABIUUQMXICR-UHFFFAOYSA-N 4-(1,2,4-thiadiazinan-4-ylmethyl)-1,2,4-thiadiazinane Chemical compound C1CSNCN1CN1CCSNC1 HMYABIUUQMXICR-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种牛磺罗定在制备抗HIV病毒药物中的应用,涉及医药技术领域。本发明首次发现牛磺罗定的新用途,即牛磺罗定在抑制HIV病毒、或者制备HIV病毒药物中的应用。牛磺罗定对人体的安全性已经得到临床实践的检测,本发明发现了牛磺罗定对HIV病毒的明显药效,为抗HIV病毒提供了强有力的理论基础和实践基础,具有开发价值和推广意义。本发明在细胞水平上检测了牛磺罗定对人类免疫缺陷病毒HIV的灭活效果,灭活效率约为73%。本发明为艾滋病的治疗提供了新的途径。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种牛磺罗定在制备抗HIV病毒药物中的应用。
背景技术
艾滋病是一种危害性极大的传染病,由感染艾滋病病毒(HIV病毒)引起。 HIV是一种能攻击人体免疫系统的病毒。它把人体免疫系统中最重要的CD4T淋巴细胞作为主要攻击目标,大量破坏该细胞,使人体丧失免疫功能。因此,人体易于感染各种疾病,并可发生恶性肿瘤,病死率较高。但目前在全世界范围内仍缺乏根治HIV感染的有效药物。
CN101274921A、CN101285813A的中国专利中公开了牛磺罗定(Taurolidine)的化学名为:4,4′-亚甲基双-(四氢-2H-1,2,4-噻二嗪)-1,1,1′,1′四氧化物,分子式为C7H16N4O4S2,分子量为:284.348,形状为白色或类白色结晶性粉末,其化学结构式如下:
可通过下述合成路线合成:
牛磺罗定是一种广谱的抗菌、抗真菌和抗内毒素的药物。主要用来预防那些患有多种与导尿管相关的血流感染病人的俊学症。也可用于治疗耳炎、胸膜积脓症、骨炎、骨髓炎、皮炎、牙周炎、牙龈炎、痤疮和各种溃疡。但目前没有被发现可以用于抗艾滋病毒的用途。
发明内容
本发明的目的是提供一种牛磺罗定的新用途,即牛磺罗定在抑制HIV病毒、或者在制备抗HIV病毒药物中的应用。
在上述技术方案中,所述的牛磺罗定可以制成注射剂、输液剂、片剂、胶囊剂等剂型,优选为输液剂。
本发明的有益效果是:
本发明首次发现牛磺罗定的新用途,即牛磺罗定在抑制HIV病毒、或者在制备HIV病毒药物中的应用。牛磺罗定对人体的安全性已经得到临床实践的检测,本发明发现了牛磺罗定对HIV病毒的明显药效,为抗HIV病毒提供了强有力的理论基础和实践基础,具有开发价值和推广意义。本发明在细胞水平上检测了牛磺罗定对人类免疫缺陷病毒HIV的灭活效果,灭活效率约为73%。本发明为HIV 病毒引发的疾病的治疗提供了新的途径。
具体实施方式
为了更好的理解本发明的实质,下面通过在细胞水平上检测牛磺罗定对人类免疫缺陷病毒HIV的灭活效果。以下提供的是由武汉微立得生物医药有限公司作出的牛磺罗定样品的灭活病毒检测报告。
1.实验材料
1.1受检测样品:
参照CN101274921A的合成方法合成牛磺罗定,配置成2%的牛磺罗定溶液,作为受检样品。
1.2细胞:MT-4,人T细胞白血病细胞,MT-4细胞的培养条件为:37℃,5%CO2加湿培养箱中培养。培养基使用含有10%FBS、100U/mL青霉素和链霉素(碧云天#ST488)的RPMI1640培养基。当细胞密度达到1×107个/mL时,将细胞培养瓶静置后,去掉培养基上清,1:5传代,并加入新鲜培养基。
1.3病毒:HIV-1,IIIB株。
1.4实验试剂:RPMI1640培养基、胎牛血清及其他实验试剂由本实验室提供。
2.实验原理及方法
HIV-1病毒感染MT-4细胞,能在MT-4细胞中大量快速复制,然后释放到细胞培养上清中,用ELISA(酶联免疫吸附测定法)检测细胞培养上清中P24蛋白(HIV衣壳蛋白),即可判断细胞培养孔中是否有HIV的复制,从而计算出样品中病毒的TCID50值。
3.实验步骤
3.1样品准备:取4个EP管,分别标记A、B、C、D。A管中为样品灭活病毒样品,即在管中加入50μL样品和450μL的HIV-1病毒原液;B管为病毒对照样品,即在管中加入50μL PBS和450μL的HIV-1病毒原液;C管为细胞毒性测试样品,即在管中加入50μL样品和450μL的RPMI1640培养基;D管为细胞对照样品,即在管中加入50μL PBS和450μL的RPMI1640培养基。
3.2样品孵育:将上述的A、B、C、D,混匀后在36.5℃水浴锅中孵育10min。
3.3样品稀释:在96孔板中,每孔加入100μL的RPMI1640培养基。将孵育后的样品每孔加25μL到96孔板的第一排孔中混匀,A、B管为6个复孔,C、D管为2个复孔。每孔取25μL混匀后,加入到下一排孔,5倍梯度稀释,7个稀释度。
3.4加细胞培养:将MT-4细胞密度调整至1.5×105,每孔加入100μL细胞悬液。将96孔板放入CO2培养箱中静置培养过夜。
3.5未进入病毒颗粒的洗涤:上述细胞板在CO2培养箱中静置培养过夜后,每孔取出150μL上清,加入150μL PBS,400rpm离心5min。去掉上清,一共清洗4次。最后加入培养基,静置培养5天。
3.6HIV P24的ELISA检测:培养5天后,每孔取出100μL上清,加入100μL 1%的Triton-X 100,37℃孵育2h。P24 ELISA检测试剂盒检测上清中P24的表达情况。阳性细胞孔标记为“+”,否则标记为“-”,用Karber法计算样品中的病毒TCID50值。
3.7样品的细胞毒性检测:在细胞毒性检测板中,每孔去掉100μL上清,加入50μLCelltire-Glo试剂,检测细胞活力,并计算细胞存活率。
4.样品灭活人类免疫缺陷病毒HIV活性检测结果
样品对人类免疫缺陷病毒HIV灭活的P24检测结果如表2所示。
表1样品对HIV的灭活作用的细胞铺板
表2样品对HIV的灭活的P24检测结果
注:“-”代表P24阴性,“+”代表P24阳性。灰色区域表示细胞存活率为10%以下。
5.总结
本次实验在细胞水平上检测了样品对人类免疫缺陷病毒HIV的灭活效果。检测结果显示HIV在受检测样品存在下,36.5℃10min作用条件下,病毒的滴度为 3.09×103TCID50/mL,而HIV病毒对照的滴度为1.17×104TCID50/mL,灭活效率约为73%。
由此可知牛磺罗定对HIV病毒的明显药效,为抗HIV病毒提供了强有力的理论基础和实践基础,具有开发价值和推广意义。牛磺罗定可用于制备抗HIV-1病毒药物。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (4)
1.一种牛磺罗定在抑制HIV病毒上的应用。
2.一种牛磺罗定在制备抗HIV病毒药物中的应用。
3.权利要求2所述的应用,其特征在于,所述的牛磺罗定的药物剂型为注射剂、输液剂、片剂、或者胶囊剂剂型。
4.权利要求3所述的应用,其特征在于,所述的牛磺罗定的药物剂型为输液剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010638924.XA CN111671758A (zh) | 2020-07-06 | 2020-07-06 | 牛磺罗定在制备抗hiv病毒药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010638924.XA CN111671758A (zh) | 2020-07-06 | 2020-07-06 | 牛磺罗定在制备抗hiv病毒药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111671758A true CN111671758A (zh) | 2020-09-18 |
Family
ID=72437696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010638924.XA Pending CN111671758A (zh) | 2020-07-06 | 2020-07-06 | 牛磺罗定在制备抗hiv病毒药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111671758A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113491700A (zh) * | 2020-07-06 | 2021-10-12 | 军事科学院军事医学研究院军事兽医研究所 | 牛磺罗定在抗病毒中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608051B1 (en) * | 1999-03-12 | 2003-08-19 | Medpointe Healthcare Inc. | Compositions and methods for treating blood |
US20060264422A1 (en) * | 2005-05-09 | 2006-11-23 | Johannes Reinmueller | Use of taurolidine as enhancer of the complement system |
CN103118669A (zh) * | 2010-06-01 | 2013-05-22 | 盖斯特里希医药公司 | 口服药物治疗方法和组合物 |
CN110776479A (zh) * | 2014-12-19 | 2020-02-11 | 盖斯特里希医药公司 | *噻嗪样化合物、其制备方法和用途 |
-
2020
- 2020-07-06 CN CN202010638924.XA patent/CN111671758A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608051B1 (en) * | 1999-03-12 | 2003-08-19 | Medpointe Healthcare Inc. | Compositions and methods for treating blood |
US20060264422A1 (en) * | 2005-05-09 | 2006-11-23 | Johannes Reinmueller | Use of taurolidine as enhancer of the complement system |
CN103118669A (zh) * | 2010-06-01 | 2013-05-22 | 盖斯特里希医药公司 | 口服药物治疗方法和组合物 |
CN110776479A (zh) * | 2014-12-19 | 2020-02-11 | 盖斯特里希医药公司 | *噻嗪样化合物、其制备方法和用途 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113491700A (zh) * | 2020-07-06 | 2021-10-12 | 军事科学院军事医学研究院军事兽医研究所 | 牛磺罗定在抗病毒中的应用 |
WO2022007713A1 (zh) * | 2020-07-06 | 2022-01-13 | 军事科学院军事医学研究院军事兽医研究所 | 牛磺罗定在抗病毒中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111588721B (zh) | 化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途 | |
Koyanagi et al. | Establishment of a high production system for AIDS retroviruses with a human T-leukemic cell line Molt-4 | |
CN112791084B (zh) | Ml-60218在制备用于治疗非洲猪瘟的药物中的新用途 | |
CN113456645A (zh) | Dmxaa在制备防治骨质疏松症药物中的应用 | |
CN111671758A (zh) | 牛磺罗定在制备抗hiv病毒药物中的应用 | |
JP2008512399A (ja) | 医薬組成物およびアルギナーゼを用いる肝炎の処置方法 | |
BRPI0513321B1 (pt) | Vírus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais | |
Salemi et al. | The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy | |
KR100294836B1 (ko) | 바이러스감염증예방치료제 | |
KR920008704B1 (ko) | 생체내에서 인간 면역결핍 비루스의 활성을 억제하는 항비루스제 | |
Vernazza et al. | High Seroprevalence of Parvovirus B19 among Patients Infected with Human Immunodeficiency Virus [with Reply] | |
CN108888628B (zh) | 一种人参皂苷GRh2在制备抗弓形虫复方制剂中的应用及其药物 | |
CN105663123B (zh) | 含吡螨胺结构的化合物在制备抗埃博拉病毒感染药物中的应用 | |
CN106957826B (zh) | 一种病毒灭活剂及其应用 | |
CN102160870B (zh) | 聚(4-苯乙烯磺酸-共聚-马来酸)钠盐的用途及其药物组合物 | |
CN111658654A (zh) | 化合物jq-1用于预防或治疗非洲猪瘟的新用途 | |
CN105726525B (zh) | 含Merochlorin A结构的化合物在制备抗埃博拉病毒感染药物中的应用 | |
CN1105238A (zh) | 抗aids病毒的药物组合物 | |
KR20010076077A (ko) | 짚신나물로부터 분리한 b형 간염바이러스 표면항원생성억제물질과 그 추출방법 및 용도 | |
CN113274406B (zh) | 氯化锰或含有氯化锰的组合物在制备用于治疗非洲猪瘟的药物中的新用途 | |
CN111100902A (zh) | 一种基于sim靶点抗kshv/ebv相关肿瘤小分子化合物筛选方法和应用 | |
CN113750083B (zh) | 二甲双胍在制备治疗手足口病的药物中的应用 | |
CN115137762B (zh) | 一种青钱柳提取物及其在制备抗冠状病毒的药物中的用途 | |
CN101347492A (zh) | 一种剑叶三宝木提取物在制备抗艾滋病病毒药物中的应用 | |
CN106214777B (zh) | 西北沼委陵菜抗hiv-1病毒有效部位及制法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200918 |